Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

419 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors.
Ruf T, Kramer R, Forschner A, Leiter U, Meier F, Reinhardt L, Dücker P, Ertl C, Tomsitz D, Tietze JK, Gutzmer R, Dabrowski E, Zimmer L, Gesierich A, Zierold S, French LE, Eigentler T, Amaral T, Heinzerling L. Ruf T, et al. Among authors: gutzmer r. Eur J Cancer. 2024 May;203:114028. doi: 10.1016/j.ejca.2024.114028. Epub 2024 Mar 27. Eur J Cancer. 2024. PMID: 38652976 Free article.
Association of antibiotic treatment with survival outcomes in treatment-naïve melanoma patients receiving immune checkpoint blockade.
Chorti E, Kowall B, Hassel JC, Schilling B, Sachse M, Gutzmer R, Loquai C, Kähler KC, Hüsing A, Gilde C, Thielmann CM, Zaremba-Montenari A, Placke JM, Gratsias E, Martaki A, Roesch A, Ugurel S, Schadendorf D, Livingstone E, Stang A, Zimmer L. Chorti E, et al. Among authors: gutzmer r. Eur J Cancer. 2024 Mar;200:113536. doi: 10.1016/j.ejca.2024.113536. Epub 2024 Jan 18. Eur J Cancer. 2024. PMID: 38306840 Free article.
Checkpoint inhibitor-induced bullous pemphigoid differs from spontaneous bullous pemphigoid.
Kramer N, Müller G, Zierold S, Röckel M, Fröhlich W, Schefzyk M, Kumbrink J, Hassel JC, Berking C, Ziemer M, Nashan D, French LE, Vera J, Kerl-French KE, Gutzmer R, Heinzerling L. Kramer N, et al. Among authors: gutzmer r. J Eur Acad Dermatol Venereol. 2024 Aug;38(8):e722-e728. doi: 10.1111/jdv.19860. Epub 2024 Feb 24. J Eur Acad Dermatol Venereol. 2024. PMID: 38400651 No abstract available.
The RANKL inhibitor denosumab in combination with dual checkpoint inhibition is associated with increased CXCL-13 serum concentrations.
Schaper-Gerhardt K, Gutzmer R, Angela Y, Zimmer L, Livingstone E, Schadendorf D, Hassel JC, Weishaupt C, Remes B, Kubat L, Spassova I, Becker JC. Schaper-Gerhardt K, et al. Among authors: gutzmer r. Eur J Cancer. 2024 May;202:113984. doi: 10.1016/j.ejca.2024.113984. Epub 2024 Mar 2. Eur J Cancer. 2024. PMID: 38479119 Free article.
Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastases.
Pires da Silva I, Li I, Ugurel S, Serra-Bellver P, Andhale A, Burnette H, Aya F, Conway JW, Braden J, Carlino MS, Menzies AM, Weichenthal M, Mohr P, Gutzmer R, Arance AM, Johnson DB, Lorigan P, Schadendorf D, Lo SN, Long GV. Pires da Silva I, et al. Among authors: gutzmer r. Eur J Cancer. 2024 Jul;205:114101. doi: 10.1016/j.ejca.2024.114101. Epub 2024 May 7. Eur J Cancer. 2024. PMID: 38735161
Stringent monitoring can decrease mortality of immune checkpoint inhibitor induced cardiotoxicity.
Wang Y, Ertl C, Schmitt C, Hammann L, Kramer R, Grabmaier U, Schöberl F, Anz D, Piseddu I, Pesch G, Vera J, Froehlich W, Weckbach L, Tomsitz D, Loquai C, Zimmer L, Mangana J, Dummer R, Gutzmer R, Klespe KC, Stege H, Meiss F, Thoms KM, Terheyden P, Bröckelmann PJ, Johnson DB, French LE, Heinzerling L. Wang Y, et al. Among authors: gutzmer r. Front Cardiovasc Med. 2024 Jun 10;11:1408586. doi: 10.3389/fcvm.2024.1408586. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 38915743 Free PMC article.
Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- ("Triple") wild type melanomas.
Jansen P, Galetzka W, Lodde GC, Standl F, Zaremba A, Herbst R, Terheyden P, Utikal J, Pföhler C, Ulrich J, Kreuter A, Mohr P, Gutzmer R, Meier F, Dippel E, Weichenthal M, Placke JM, Landsberg J, Möller I, Sucker A, Paschen A, Hadaschik E, Zimmer L, Livingstone E, Schadendorf D, Ugurel S, Stang A, Griewank KG. Jansen P, et al. Among authors: gutzmer r. Eur J Cancer. 2024 Sep;208:114208. doi: 10.1016/j.ejca.2024.114208. Epub 2024 Jul 6. Eur J Cancer. 2024. PMID: 39018633 Free article.
A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma - Results of systematic literature research.
Amaral T, Nanz L, Higuita LMS, Ascierto P, Berking C, Couselo EM, Donia M, Dummer R, Gutzmer R, Haushild A, Jalving M, Lee R, Lorigan P, Marquez-Rodas I, Michelin O, Nathan P, Robert C, Schadendorf D, Sobczuk P, Flatz L, Leiter U, Garbe C. Amaral T, et al. Among authors: gutzmer r. Eur J Cancer. 2025 Jan 17;215:115160. doi: 10.1016/j.ejca.2024.115160. Epub 2024 Dec 13. Eur J Cancer. 2025. PMID: 39673834 Free article.
Adjuvant treatment with vindesine in comparison to observation alone in patients with metastasized melanoma after complete metastasectomy: a randomized multicenter trial of the German Dermatologic Cooperative Oncology Group.
Eigentler TK, Radny P, Hauschild A, Gutzmer R, Linse R, Pföhler C, Wagner SN, Schadendorf D, Ellwanger U, Garbe C; German Dermatologic Cooperative Oncology Group. Eigentler TK, et al. Among authors: gutzmer r. Melanoma Res. 2008 Oct;18(5):353-8. doi: 10.1097/CMR.0b013e32830e3936. Melanoma Res. 2008. PMID: 18781134 Clinical Trial.
419 results